Nucleic acids useful for triggering tumor cell lethality

US7595302B2 · kind B2 · utility

Assignees

• INSTITUT CURIE · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• MUSEUM NATIONAL D'HISTOIRE NATURELLE · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

• Marie Dutreix · L'Haÿ-les-Roses, FR
• Jian Sun · Saint-Maur-des-Fossés, FR

Key dates

• Filing date: Oct 25, 2004
• Grant date: Sep 29, 2009
• Expiry date: Apr 15, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to double-stranded nucleic acid fragments comprising a chemically modified backbone and at least 4-1000 bp, preferably 8-500 bp, and most preferably 16-200 bp. The disclosed molecules (DRIL molecules) may interfere with DNA damage signaling and repair pathways, in particular the non homologous NHEJ pathway of double-stranded break repair. The invention discloses the application of the DRIL molecules as adjuvant compositions to be used in association with a DNA breaking treatment, particularly radiotherapy or chemotherapy, in combination with a pharmaceutically acceptable carrier, in an efficient amount to be introduced in the tumoral cell nuclei in order to trigger DNA repair induced lethality (DRIL in short) of tumoral cells/tissues.